EAM Investors LLC trimmed its position in CymaBay Therapeutics Inc (NASDAQ:CBAY) by 8.4% in the fourth quarter, HoldingsChannel reports. The firm owned 543,815 shares of the biopharmaceutical company’s stock after selling 50,189 shares during the period. CymaBay Therapeutics comprises 0.7% of EAM Investors LLC’s investment portfolio, making the stock its 26th largest holding. EAM Investors LLC’s holdings in CymaBay Therapeutics were worth $5,003,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Bank of New York Mellon Corp raised its stake in CymaBay Therapeutics by 0.8% during the second quarter. Bank of New York Mellon Corp now owns 17,344 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 140 shares in the last quarter. Virtu Financial LLC raised its stake in CymaBay Therapeutics by 56.2% during the fourth quarter. Virtu Financial LLC now owns 24,735 shares of the biopharmaceutical company’s stock worth $228,000 after acquiring an additional 8,899 shares in the last quarter. Sigma Planning Corp raised its stake in CymaBay Therapeutics by 82.0% during the fourth quarter. Sigma Planning Corp now owns 27,300 shares of the biopharmaceutical company’s stock worth $251,000 after acquiring an additional 12,300 shares in the last quarter. Schwab Charles Investment Management Inc. acquired a new position in CymaBay Therapeutics during the fourth quarter worth $115,000. Finally, Baird Financial Group Inc. raised its stake in CymaBay Therapeutics by 26.8% during the fourth quarter. Baird Financial Group Inc. now owns 107,449 shares of the biopharmaceutical company’s stock worth $989,000 after acquiring an additional 22,712 shares in the last quarter. Institutional investors and hedge funds own 60.12% of the company’s stock.
Several research firms have issued reports on CBAY. BidaskClub upgraded CymaBay Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, February 21st. Evercore ISI began coverage on CymaBay Therapeutics in a research note on Tuesday, February 13th. They set an “outperform” rating for the company. ValuEngine upgraded CymaBay Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Zacks Investment Research upgraded CymaBay Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, January 26th. Finally, Roth Capital reiterated a “buy” rating and set a $27.00 price objective on shares of CymaBay Therapeutics in a research note on Thursday, January 25th. Two research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. CymaBay Therapeutics presently has an average rating of “Buy” and an average target price of $16.56.
Shares of CymaBay Therapeutics Inc (NASDAQ:CBAY) opened at $14.62 on Tuesday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 7.39 and a current ratio of 7.39. The company has a market capitalization of $814.51, a price-to-earnings ratio of -14.33 and a beta of 2.36. CymaBay Therapeutics Inc has a 1-year low of $2.81 and a 1-year high of $15.49.
WARNING: This report was first posted by Ticker Report and is owned by of Ticker Report. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://www.tickerreport.com/banking-finance/3226090/eam-investors-llc-sells-50189-shares-of-cymabay-therapeutics-inc-cbay.html.
CymaBay Therapeutics Company Profile
CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.
Want to see what other hedge funds are holding CBAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CymaBay Therapeutics Inc (NASDAQ:CBAY).
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.